Document Type : CASE REPORT
Authors
1 Department of Pediatric Endocrinology and Metabolism, Ilam University of Medical Sciences, Ilam; Endocrine and Metabolism Research Center, University of Medical Sciences, Isfahan, Iran
2 Department of Pediatric Endocrinology, Endocrine and Metabolism Research Center, Isfahan, Iran
3 Child Growth and Development Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
Abstract
Tyrosinemia type III is an autosomal recessive disorder caused by the deficiency of 4- hydroxyphenylpyruvate dioxygenase (4-HPPD). It is characterized by elevated levels of blood tyrosine and massive excretion of its derivatives into the urine. Clinical findings of tyrosinemia type III include neurological symptoms and mental retardation. Only a few patients presenting with this disease have been described, and the clinical phenotype remains variable and unclear. We present a case, who was admitted to the hospital at the age of 4 months for recurrent seizures. Two months later, she was admitted again with status epilepticus. Laboratory data showed increased level of tyrosine in the blood. She was treated with a diet low in tyrosine and phenylalanine and anamix formula that leading to catch-up growth and improvement of her symptoms. Plasma tyrosine level dropped to normal values. In any child who presents with the neurologic symptom, some rare diagnosis like tyrosinemia type III should be considered.
Keywords
1. | |
2. | |
3. | |
4. | |
5. |
Heylen E, Scherer G, Vincent MF, Marie S, Fischer J, Nassogne MC. Tyrosinemia Type III detected via neonatal screening: Management and outcome. Mol Genet Metab 2012;107:605-7. [PUBMED] |
6. |
Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 1992;340:813-7. [PUBMED] |
7. |
Nakamura K, Tanaka Y, Mitsubuchi H, Endo F. Animal models of tyrosinemia. J Nutr 2007;137:1556S-60. [PUBMED] |
8. |
Endo F, Kitano A, Uehara I, Nagata N, Matsuda I, Shinka T, et al. Four-hydroxyphenylpyruvic acid oxidase deficiency with normal fumarylacetoacetase: A new variant form of hereditary hypertyrosinemia. Pediatr Res 1983;17:92-6. [PUBMED] |
9. |
Awata H, Endo F, Matsuda I. Structure of the human 4-hydroxyphenylpyruvic acid dioxygenase gene (HPD). Genomics 1994;23:534-9. [PUBMED] |
10. | |
11. |
Ellaway CJ, Holme E, Standing S, Preece MA, Green A, Ploechl E, et al. Outcome of tyrosinaemia type III. J Inherit Metab Dis 2001;24:824-32. [PUBMED] |
12. | |
13. | |
14. | |
15. |